Compounds were assessed for their ability to modulate ERα protein levels in MCF7 breast cancer cells using a quantitative In-Cell Western (ICW) immunofluorescence assay, which enabled determination of compound potency and maximal activity in a high throughput format. The gene discussed is ESR1; the disease is breast cancer.